Cargando…
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice
Drug development for Alzheimer’s disease has endeavored to lower amyloid β (Aβ) by either blocking production or promoting clearance. The benefit of combining these approaches has been examined in mouse models and shown to improve pathological measures of disease over single treatment; however, the...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940263/ https://www.ncbi.nlm.nih.gov/pubmed/29626114 http://dx.doi.org/10.1084/jem.20171484 |